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Abstract 
Recent years have seen a marked diversification of excipient based formulation strategies 
used for the development and commercialisation of dry powder inhaler (DPI) products. 
These innovative approaches not only provide benefits to patients and health care 
professionals through the availability of a wider range of therapeutic DPI products, but, 
importantly, also allow formulators to exploit the potential opportunities that excipients 
provide for the development of DPIs. Whilst many DPI products have, and continue to be 
developed using a single formulation excipient, the commercialisation of DPI products which 
contain the two excipients lactose monohydrate and magnesium stearate, namely the ‘dual 
excipient platform’ has recently been achieved. This article provides an overview of the 
background and current status of the development of such ‘dual excipient platform’ based 
DPI products.  
Keywords: Dry powder inhaler, excipients, formulation, inhalation 
1. Introduction 
Medicaments have been delivered to the respiratory tract for thousands of years with this 
route of administration now established as a standard and valuable drug delivery tool in the 
physician’s armoury. Throughout history, the fundamental goal of drug delivery to the lungs 
has essentially remained unchanged, namely to generate and deliver a targeted efficacious 
dose of active ingredient to the patient. This is equally true in the modern respiratory era 
where many approved drugs are now routinely delivered to the patient using the very 
different, but well understood delivery devices including pressurised metered dose inhalers 
(pMDIs), nebulisers and DPI delivery platforms. As with early forms of drug delivery to the 
respiratory tract, such modern delivery systems also contain formulation ingredients other 
than the drug substance. Whilst ancient texts, such as the Ebers papayrus, and apothecaries 
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may not have defined them, most ancient formulas, and indeed formulas until the end of 
the 19th century, contained additional materials; what we would in the present day refer to 
as, ‘excipients’ (Anderson, 2005; Sanders, 2007). Excipients now form one of the key 
cornerstones for the development of a vast majority of medicines. Pharmaceutical 
development strategies are often progressed based on understanding the functionality of 
excipients, and, importantly, their relationships to the processability and properties of any 
final dosage form. Since the primary task of development is to achieve the 
commercialisation of pharmaceutical drug products which can be manufactured consistently 
to meet defined quality attribute specifications, improvements that can be gained from any 
aspects of the drug product manufacturing processes would be beneficial for patient 
outcomes. This is true for excipients, which often form the major component of drug 
products, where their unique, and importantly, multi-functional properties have allowed 
their use as drug delivery vehicles in a wide range of dosage forms, including respiratory 
products, including DPIs.   
2. Respiratory therapy: The modern era and the dawn of the excipient age 
The modern era of drug delivery to the lungs using DPIs essentially began in the 1940’s with 
the appearance of the first approved commercial DPI product, namely the Abbott 
Aerohaler®, from Abbott Laboratories, USA. This product was used to deliver penicillin and 
norethisderone and contains many features which would be recognisable today, in that it 
uses a small capsule reservoir (also described as a ‘sifter’) containing a lactose based 
formulation, designed to be used in a device which utilises the patient generated inspiratory 
airflow to disperse the therapeutic particles in an airstream (Fields, 1949; Sanders, 2007). It 
is particularly interesting to note that in the original 1949 Abbott Laboratories patent for 
this product, the inventor, Mack Fields, described the rather insightful claim that ‘smoother 
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and more accurate mechanical action can be secured by mixing the penicillin with at least a 
little other material intended to function as a diluent or vehicle’, an early reference to the 
functionality, and importance, of an additional ‘material’; i.e. the ‘excipient’. 
 
Whilst many attributes, and concepts, of the Abbott Aerohaler® are common in the current 
DPI arena, it was only in the 1960’s with the development of the single unit dose gelatin 
capsule based product, the Intal®Spinhaler®, that researchers began to investigate the 
potential applications and functionality of excipients in DPIs. For example, as early as 1971 
the importance of particle size distribution characteristics for the dispersion of lactose and 
formulations of (di)sodium cromoglycate and lactose from a Spinhaler® was described by 
Bell et al. (1971). The Intal®Spinhaler® proved to be the forerunner to the development and 
commercialisation of many ‘drug only’ and excipient based DPI products (Healy et al., 2014; 
Yang et al., 2014). Whilst the formulation approaches to DPIs during this era of expansion 
remained relatively unchanged, essentially using a ‘single excipient platform’ (SEP) based on 
micronised drug substance and a single excipient, lactose monohydrate, this period also saw 
further advances in the scientific understanding of the interactions between the 
components of DPI products, namely the drug substance, excipient, container system and 
device. These scientific advances have enabled the successful development of a 
technologically diverse and elaborate range of excipient based reservoir, capsule and blister 
formulation container closure systems for the delivery of mono and combination drug 
therapies.   
3.  Excipient platforms in commercialised DPIs 
Even though the development of DPI products requires a somewhat different, and unique, 
set of considerations compared to more standard oral solid dosage forms, it is important to 
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remember that the general role of excipients in DPI products is essentially the same as for 
all pharmaceutical products, namely to impart functionality to the formulation so as to 
enable the manufacture of a robust, stable and reproducible drug product which maintains 
its potency over its entire shelf-life. The establishment of a dose range and dosing regimen 
provides an efficacious and safe medicine for the patient and development studies based on 
identifying critical quality attributes using quality by design can elucidate the approaches 
available to develop a commercial product, thereby allowing appropriate product 
specifications to be developed, and achieved. The tailoring of any such development 
strategies can impact the development timelines and the product performance and stability 
profiles and hence any achievable product efficacy and shelf-life. The solution of these often 
conflicting challenges is the conundrum of pharmaceutical development, for which 
excipients can play a key role. This is especially true for DPI products, not only in view of 
their route of administration, but also in that they are typically very low dose products 
compared to standard oral solid dosage forms. Consequently, robust and often specialised 
analytical methodologies and techniques are required to control the qualities of the final 
drug product and its components during development and, importantly, commercialisation.  
 
The successful commercialisation of many mono and combination DPI drug therapies 
demonstrates that such development challenges can be readily surmountable for 
micronised drug substances in SEPs. However, the turn of the 21st century has seen a sea 
change in how users, and regulators, consider the wider potential, applicability and control 
of excipients in DPI products. For example, the importance of excipient quality, 
characteristics and functionality is reflected not only in the increasingly demanding 
regulatory and GMP frameworks for excipients, but also by their inclusion in sections of the 
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European and US regulatory guidance for inhaled products, which form part of the global 
regulatory environment for the submission of DPI product dossiers to health authorities for 
obtaining marketing authorisations.  
4. The single excipient platform 
The SEP has been the most prevalent excipient strategy used in modern commercial DPI 
products and is defined as a final formulation, which consists of one or more active 
pharmaceutical ingredients (APIs) and a single excipient, regardless of any blending, mixing 
and particle manipulation steps. The majority of approved SEP DPI products have been 
developed based on the well-known ‘carrier’ approach, however, the use of a single 
excipient in DPI formulations now also encompasses systems based on elaborate particle 
engineering technologies. 
5. ‘Carrier’ based DPI formulations and products 
As previously stated, many commercialised DPI products have been developed based on 
using a single excipient in the formulation. The vast majority of these products contain 
lactose monohydrate as the excipient in so called ‘carrier’ and ‘agglomerate’ based 
formulations where the excipient is used to aid the dosing of the drug and to modify the 
cohesive nature of micronised drug substances which directly influences DPI characteristics 
such as blend uniformity, content uniformity, manufacturability and ultimately, aerosol dose 
delivery performance characteristics. Indeed, there is perhaps no other solid dosage form 
where so many aspects of the final drug product manufacturing and performance are 
dependent on the multi-functional properties of a single excipient. However, it should be 
emphasized that while these SEP excipients are described as ‘carriers’ for DPI products, their 
actual functionality extends far further. For example, drug product expiry dates of 18 to 24 
months at 25 degrees Centrigrade storage conditions are readily achievable, suggesting that 
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a stable product can be commercialised without any additional, and unnecessary and costly, 
formulation/excipient manipulation. In such cases, the excipient may be providing stability 
to the formulation and drug product, however, when the target acceptable expiry date is 
achieved, any ‘stabilising’ functionality is often not in evidence, or ‘claimed’.  
5.1 The functionality of the ‘carrier’ excipient in SEP DPI formulations and products 
The role, or functionality, of the single excipient in SEP based DPI products has traditionally 
been described as a ‘dispersant’, ‘filler’, ‘diluent’ or ‘carrier’. In particular, the latter term is 
somewhat unique to DPI’s and was used as early as the 1970’s by Hartley and Gunning 
(1976) to describe the role of lactose in DPI formulations of sodium chromoglycate. 
Investigations into the physical properties of pharmaceutical powder mixtures began in 
earnest in the 1970’s and 1980’s where researchers including Travers, Hersey, and 
Staniforth, and their co-workers, published a series of articles relating to the interactions 
between particles in powder beds in what were then described as so-called ‘ordered 
mixtures’ or ‘adhesive mixtures’ (Travers, 1971; Hersey, 1975; Lai et al., 1981; Staniforth et 
al., 1982). The importance of this growing area of scientific interest was recognised in the 
British Pharmaceutical Conference Science Award Lecture ‘Order out of Chaos’, presented 
by John Staniforth in 1986 (Staniforth, 1987).  
 
Even though many of these early reports used the phrase ‘carrier’ to describe the larger 
particle sized component in binary powder mixtures, these studies were primarily focused 
on the evaluation of the properties of the powders in relation to standard tablet and 
capsule based solid dosage forms, for example, segregation and homogeneity, and not their 
role in inhaled products. Since these early fundamental studies a plethora of scientific 
literature, reviews and patents has appeared describing the interactions of particles in 
 8 
 
powder mixtures, including various aspects of ‘carrier’ based DPI’s and researchers are 
continuing to elucidate the relationships between the properties of ‘carrier’ excipients and 
drug substances, and their impact on pharmaceutical performance. For example, for such 
formulations, it is now accepted that particle size distribution of the ‘carrier’ excipient is 
critical for product performance, and requires appropriate controls. 
 
Additionally, the increasingly universal use of terms such as ‘adhesive mixture’ and ‘carrier’ 
to describe formulations and excipients in DPI’s has led to their appearance in regulatory 
relevant documents. For example, in 2012, the description ‘adhesive mixture’ was used in 
the public European Committee for Medicinal Products for Human Use (CHMP) assessment 
documentation (EMA/CHMP/303918/2012) to describe the micronised aclidinium bromide 
and lactose monohydrate formulation in the DPI product, Bretaris®Genuair®. Moreover, the 
‘carrier’ description is now so commonplace in academic, industrial and regulatory circles 
that in 2014 it was incorporated into the updated respiratory section of the United States 
Pharmacopoeia general chapter <1059> Excipient Performance (United States 
Pharmacopoeia, 2016) and also appears in the public CHMP assessment documentation of 
several recently approved DPI products, for example, EMA/659981/2009 for 
Onbrez®Breezhaler®, approved in 2009. Such ‘carrier’ excipients, often of a small particle 
size, are also used in what are described as ‘agglomerate’ formulations, where the 
functionality of the excipient is similar to the ‘carrier’ based systems, for example in 
Symbicort®Turbohaler®.  
 
Developing such SEP based products is a challenging and often a semi-empirically driven 
process. However, pathways for the development of lactose monohydrate based ‘carrier’ 
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and ‘agglomerate’ formulations containing micronsied drug substances presently consist 
primarily of standard robust unit process operations, such as micronisation, blending, filling 
and packaging. Even though the use of such processes in DPI products is somewhat unique 
to this sector of the pharmaceutical industry, their impact on the final drug product is well 
understood. These processes have been successfully used to commercialise many 
originator, and more recently, generic DPI products. Even though the vast majority of 
marketed SEP ‘carrier’ based DPI products contain lactose monohydrate, single excipient 
‘carrier’/’agglomerate’ based DPI products have also historically been commercialised 
utilising anhydrous glucose (Atrovent®Aerocaps®) and anhydrous lactose 
(Asmanex®Twisthaler®) in single dose capsule and reservoir devices, respectively. Even 
though such ‘anhydroglucose’ containing excipients exhibit similar physicochemical 
characteristics to lactose monohydrate, the development of DPI products using these 
alternative excipients is not without risk, and represents the first signs of a willingness to 
investigate and innovate new excipient delivery platforms, an interesting indication of 
future development scenarios.  
6. Particle engineered single excipient based DPI formulations and products 
The use of excipients in SEP DPI products beyond the traditional functional role of ‘carrier’ 
has also been realised with the approval of Bronchitol®, approved in Europe in 2012 
(EMA/CHMP/121817/2012), and Afrezza®, approved in the US in 2014. The approval of 
these two products not only represents advances in innovation in the respiratory sector, but 
also a step change in the technological and regulatory approaches to the so-called SEP, 
which should not be underestimated in terms of their achievement. From the publically 
available regulatory product reviews, patient information and literature, both of these 
products not only contain elaborately engineered particles but also novel DPI excipients, 
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with the former, developed by Pharmaxis, containing spray-dried engineered mannitol, see 
Figure 1 which is the actual efficacious agent (atypical active) (Hurt and Bilton, 2012), and 
the latter, fumaryl diketopiperazine, see Figure 2. Afrezza® was originally developed by 
MannKind Corporation as Technosphere® for delivery of insulin to the systemic circulation 
via the lungs and this delivery platform is based on the elaborate self-assembly properties of 
the propriety excipient, fumaryl diketopiperazine, a substituted diketopiperazine (Leone-Bay 
and Grant, 2006). Mannitol is also marketed in several countries as Aridol®/Osmohale®, a 
capsule based DPI indirect diagnostic osmotic bronchial challenge test that can be used to 
identify bronchial hyper-responsiveness. Additionally, other sophisticated SEP particle 
engineering technologies are also being developed for the respiratory sector by companies 
such as Liquidia (Garcia et al., 2012).  
 
Even though both the ‘carrier’ and, more recently, particle engineering, SEP strategies 
continue to be successful and widely used in commercialized DPIs, this does not mean that 
other, multiple excipient based platforms, have not been explored by the respiratory sector 
and DPI products based on using two or more excipients indeed, have  been 
commercialised. For example, the use of multiple excipients in DPI products has been 
realised with the approval of Exubera™, and  more recently, TOBI®Podhaler®, but perhaps 
the most notable and more broadly applied new excipient platform strategy for the 
development of DPI’s used to date is the ‘dual excipient platform’ (DEP) where lactose 
monohydrate is used in conjunction with a second, ternary, excipient, namely magnesium 
stearate. 
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 7. The dual excipient platform 
Whilst the ‘carrier’ based SEP approach has been demonstrated to be more than capable of 
supporting the development and commercialisation of many originator, and to a lesser 
extent, generic DPI products, there may be instances where the use of such historical ‘single 
excipient’ approaches may not be appropriate for the development of some DPI products, 
especially in standard capsule and/or blister container systems. For example, the use of a 
SEP may not be capable of achieving the required performance efficiency, manufacturability 
and scale or commercial shelf-life using well understood product and company specific 
‘carrier’ excipient based processing steps. Additionally, the SEP may not be readily 
adaptable for intellectual property reasons or for the matching of generic DPI’s to their 
originator products.  
 
In terms of new approaches for the commercialisation of DPI products, recent development 
strategies have focused on maintaining a well understood and established inhaler device, 
container systems and manufacturing processes, whilst modifying the functionality of the 
formulation by the addition of a single ternary material, and in particular, an excipient, and 
most notably, magnesium stearate; creating a ‘dual excipient platform’. Such a DEP can be 
considered as a highly functional excipient system in which a second (ternary) excipient  is 
added during one or more of the manufacturing unit operation(s) at a certain final level to 
impart a required property to the final formulation and drug product rather than any simple 
blending, mixing or manipulation of the same single excipient. However, it should be 
considered that any added material may also inadvertently impart functionality to another 
aspect of the drug product in addition to modifying the targeted functional characteristic, 
which is important for any intellectual property considerations.  
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7.1 The dual excipient platform in commercial DPI products 
Whilst there has been a considerable number of academic publications and patents 
concerning the use of additional (ternary) excipients as functional additives for DPI’s, their 
use in approved products has expanded since 2010 with no less than 6 product approvals by 
3 sponsors in global regional markets between 2010 and 2015, all of which contain lactose 
monohydrate and magnesium stearate, see Table 1.  
 
The approval of these products also demonstrates the applicability of the ternary excipient, 
magnesium stearate, in different lactose monohydrate based DPI delivery platforms, 
namely, capsule, blister and reservoir. One interesting additional aspect of such approvals is 
that the sponsors of these products appear to be also adopting internal flexible 
development approaches in that they have commercialised products which contain both a 
single excipient, lactose monohydrate, and products which contain two excipients, namely, 
lactose monohydrate together with the ternary, additional, excipient, magnesium stearate. 
In view of the number of successful capsule, blister and reservoir based DPI product 
approvals which contain magnesium stearate it can be argued that such a development 
strategy is now becoming an industry and regulatory ‘standard’. However, the successful 
development of any new excipient platform in DPIs represents real scientific and 
technological innovation by the industry.  
7.2 The functionality of magnesium stearate in DEP DPI formulations and products 
Magnesium stearate is produced from animal and vegetable sources and is a well-known 
excipient, which is widely used a lubricant is sold dosage forms. However, as with many 
excipients, magnesium stearate is not a single pure chemical entity, and in this case, the 
commercial excipient exists as a composite/mixture of magnesium salts of stearic acid and 
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palmitic acid (Allen and Luner, 2009). The traditional role of magnesium stearate in solid 
dosage forms has also been expanded to DPIs where its functionality in DEP formulations 
has been described in the literature as a ‘lubricant’, ‘force control agent’, ‘water barrier’, 
‘stabiliser’ and ‘chemical stabiliser’, which are discussed in the following Sections, 
suggesting multi-functional properties of this excipient in this solid dosage form. 
 
7.3 Magnesium stearate as a lubricant in DEP DPI formulations and products 
The pre-curser to what we now recognise as the DEP really began in the 1980’s. One of the 
first roles for a ternary additional material in a DPI product was described by Chiesi and 
Pavesi in 1987 for the alleviation of potential issues with the mechanical dosing mechanism 
in a reservoir type DPI device. The functional property of the ternary materials described, 
including magnesium stearate and sodium benzoate, was described as a ‘lubricant’, which is 
the widely accepted pharmaceutical functionality of such excipients (Chiesi and Pavesi, 
1987). The first modern era DEP DPI product, Pulvinal®Beclometasone® (Chiesi), see Figure 
3, a lactose monohydrate based reservoir device product, available in three dose strengths 
of beclometasone dipropionate, which, according to the patient information leaflet also, 
importantly, contained magnesium stearate, was approved in the UK in 2001. This was 
followed in 2004 by the approval of the Novartis reservoir based multi-dose DPI product, 
Foradil®Certihaler®, which also used a DEP of lactose and magnesium stearate. The approval 
of these two products represents innovative and novel formulation approaches for the 
commercialisation of DPI products. 
 
However, even though the earlier Pulvinal®Beclometasone® product was successfully 
developed and received a marketing authorisation, there were no initial reports of any other 
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potential functionality advantages that such ternary materials may offer in terms of DPI 
product performance. 
7.4 Magnesium stearate as a performance enhancer in DEP DPI formulations and 
products 
It did not take long, however, before investigators began to study the effect of ternary 
materials on the properties of powders and DPI product performance. In terms of the use of 
magnesium stearate, reports by workers such as Staniforth and co-workers had already 
described the influence of a ternary component, magnesium stearate, on the adhesion of 
salicylic acid to sucrose (Staniforth et al., 1982). Such observations were further elaborated 
for the potential advantages of ternary materials for DPI product performance and patents 
and scientific literature began to appear at the turn of the 21st century, claiming that the 
addition of ternary materials, such as magnesium stearate, could improve the fine particle 
dose performance characteristics of DPI formulations (Brambilla et al., 2003; Chiesi et al., 
2001; Musa et al., 2003; Staniforth, 1997; Zhou and Moreton, 2012). Since this time many 
patents have appeared describing the use of excipient ‘combinations’, with these patents 
typically describing formulations containing dual excipient ‘mixtures’ of lactose 
monohydrate and a ternary material, including magnesium stearate. The use of lactose 
monohydrate and magnesium stearate as an excipient template for DPI development was 
further expanded with technology platforms such as Powderhale® (Vectura) and 
SkyeProtect® (SkyePharma) appearing. 
7.5 Magnesium stearate as a force control agent in DEP DPI formulations and products 
Whilst the use of such ternary materials in DEP DPI products may now be considered to be a 
somewhat standard approach, it should not be underestimated what this technological 
achievement represented in terms of modern DPI development and, importantly, regulatory 
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approval. With the increased understanding of the surface and particulate interactions in 
DPI’s (Price et al., 2002; Begat et al., 2004; de Boer et al., 2012), the use of such ternary 
materials in modern DPI development has led to the functionality of such a performance 
enhancer to also now being widely referred to as a ‘force control agent’ (Begat et al., 2005; 
Begat et al., 2009). Where such additives were added to DPI’s their function was invariably 
to modify the characteristics of the powder formulation by impacting the inter-particulate 
interactions, or ‘cohesive-adhesive balance’ resulting in improved powder properties and 
aerosolisation performance.  
7.6 Magnesium stearate as a water barrier in DEP DPI formulations and products 
It has been reported that the presence of magnesium stearate in DPI lactose monohydrate 
formulations results in not only the generation of a higher, but more stable fine particle 
mass, which was explained in terms of the functional ability of magnesium stearate to 
protect the formulation from moisture, representing yet another possible functional 
‘stabilising’ role for ternary materials in DPI products (Guchardi et al., 2008; Keller and 
Müller-Walz, 2001). 
7.7 Magnesium stearate as a stabiliser in DEP DPI products 
The previous sections described the functionality of the ternary material magnesium 
stearate in DEP formulations and products. It is clear that the presence of magnesium 
stearate can, in some cases, impart beneficial properties to DPI DEP formulation products 
and it can be argued that any such improvements can be described, to some degree, as 
stabilising effects. However, the true benefit of any possible improvements to any DPI 
performance characteristic can only be fully elucidated after the evaluation of their 
performance during stability assessment over a commercially acceptable shelf-life.   
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Any decisions for pharmaceutical product development strategies are based on both 
commercial and development considerations. This is equally true for DPI products where 
the fundamental goal of pharmaceutical development remains the same: to develop the 
required marketed form of a drug product, whether this be for an originator or generic 
product, in an appropriate timeframe. Whilst this naturally focusses on the needs of 
patients in terms of disease state, therapy, outcomes, compliance etc., the achievement of 
an acceptable product shelf-life is a pre-requisite for the commercialisation of a drug 
product and this is often a major challenge during development and the subsequent 
defining of the product specifications (Capen et al., 2012). Whilst early development 
stability studies can provide indications of DPI product performance and allow the 
assignment of a shelf-life in the various global climate temperature and humidity zones 
there may be situations where the expected stability profile for commercialisation may not 
be achievable using standard and well understood materials and processes, especially in SEP 
products. Clearly, in such instances simple modifications of the manufacturing processes or 
levels, and ranges, of functionality provided by the device/container system, packaging, 
storage conditions, drug substance or the single excipient may not be sufficient to achieve, 
or maintain, an acceptable level of a particular critical drug product quality attribute.  
  
In general, two types of stability profiles are exhibited by pharmaceutical drug products 
during storage time namely, constant and non-constant. The constant stability profiles 
consist of quality attributes stability indicators which have little or no variability during time 
when stored at the long term storage condition, with any apparent changes being a 
consequence of product or method variability. The non-constant stability profiles contain 
quality attributes which either increase or decay during storage at the long term storage 
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condition. It is the products which exhibit non-constant stability profiles which pose the 
greatest challenge for the commercialisation of a product since an acceptable shelf-life may 
not be achievable due to, for example, the early occurrence of out of specification events. 
Whilst out of specification results may not impact toxicity (e.g. not associated with 
increased levels of impurities), they can sometime impact the efficacy of the drug product. 
In many cases, any well understood decaying or increasing specification stability indicating 
parameter can be controlled to exhibit an acceptable sustained stability profile, allowing an 
acceptable shelf-life to be achieved, represented for decaying stability profiles in Figure 4. 
For example, the rate of any detrimental physico-chemical interactions in the product may 
be reduced by refrigeration, API salt form and hydration state, formulation and device 
design and processing and packaging configurations. However, such control measures may 
not always readily achieve the required outcomes for some development programs or be 
commercially viable and alternative strategies need to be considered. This is especially true 
for capsule and blister based DPI products, where, for example, any moisture ingress 
occurring during storage may influence the long term performance of the product, see 
Figure 5.  
7.8 The use of magnesium stearate as a stabiliser in DEP blister based DPI products 
From a development, scientific and innovation perspective, perhaps the most interesting of 
the DEP approved products are the GSK blister based products 
Relvar®Ellipta®/Breo™Ellipta™ and Anoro®Ellipta®/Anoro™Ellipta™, not only for their use of 
the ‘dual excipient platform’ but that they also utilise new device delivery systems, albeit 
still blister based, compared to the previous generation of products. These two products are 
combination products, but in contrast to the precursor combination product, 
Seretide®Accuhaler®/Advair™Diskus™, where the 2 APIs, salmererol xinafoate and 
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fluticasone propionate, are ‘co-formulated’ into a single blister in a single blister strip, the 
two APIs in Relvar®Ellipta®/Breo™Ellipta™, namely vilanterol trifenatate and fluticasone 
furoate, and Anoro®Ellipta®/Anoro™Ellipta™, namely vilanterol trifenatate and 
umeclidinium bromide, are each separately formulated into single mono therapy blisters in 
two individual blister strips, within their respective dual blister devices. This packaging 
strategy may be useful to avoid drug-drug incompatibility or formulation quality changes 
during storage. 
 
The public US prescribing information for the two new GSK combination products suggest 
that the four mono drug formulations in each of the two blisters in the two products contain 
approximately 12.3 - 12.4 mg of lactose monohydrate so that the total single formulation 
masses are 12.5 mg, with the public European product characteristics information stating 
that the delivered dose from the two products is approximately 25 mg of lactose 
monohydrate. This single blister formulation fill mass of 12.5 mg is similar to the 
formulation mass in the single blisters in the Seretide®Accuhaler®/Advair™Diskus™ co-
formulated combination product. Additionally, the public US prescribing information also 
states that the vilanterol trifenatate and umeclidinium bromide formulations also contain 
magnesium stearate, at the levels of 125 µg and 75 µg, respectively, see Table 2 for the 
formulation compositions of Anoro®Ellipta®/Anoro™Ellipta™. These differences suggest that 
the magnesium stearate levels may require adjusting in different formulations to optimise 
and achieve the desired functional benefits. Typical scanning electron microscopy images of 
the umeclidinium bromide and vilanterol trifenate formulations in Anoro®Ellipta® are shown 
in Figure 6. It can be seen from Figure 6 that the formulations exhibit particle characteristics, 
which are typical for lactose based DPI formulations, suggesting that the use of magnesium 
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stearate in these DEP products has not modified the macroscopic particle characteristics of 
the formulations. 
 
In contrast, from the public US prescribing information, the related approved GSK mono 
therapy product Arnuity®Ellipta® (fluticasone furoate), the second drug component in 
Relvar®Ellipta®/Breo™Ellipta™, only contains the excipient lactose monohydrate in the 
formulation, suggesting that in this case, the functional properties of the formulation are 
sufficient without the addition of the ternary excipient, magnesium stearate. However, the 
mono therapy of umeclidinium bromide, Incruse™Ellipta™, contains magnesium stearate at 
similar levels to the umeclidinium bromide formulation in the combination product, 
Anoro®Ellipta®/Anoro™Ellipta™. This again demonstrates the continuing flexible, and 
innovative, development approaches used during product development.   
  
In terms of the functional development of ternary excipients in such DEPs it is equally 
interesting to note that the public CHMP assessments of Anoro®Ellipta® and Relvar®Ellipta® 
describes the functionality of the magnesium stearate in the vilanterol trifenatate 
formulation as both a ‘stabiliser’ and ‘chemical stabiliser’, and in the umeclidinium bromide 
formulation as a ‘stabiliser’, with the functionality of lactose being described as a 
‘carrier/diluent’, see Table 2. This ‘stabilising’ functionality description is a widening of the 
accepted role and functionality of such ternary agents and ‘force control agents’, and should 
not be over-emphasised in terms of the implications for DPI development, for both 
originator and generic products.   
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In terms of stabilising ternary excipients used in DPIs, the use of sugar esters, such as 
cellubiose acetate, to inhibit or reduce the chemical interactions between an API and a 
carrier, and thereby reducing chemical degradation, was described by Monteith and co-
workers (Monteith et al., 2006a; Monteith et al., 2006b). The use of ternary derivatised 
carbohydrates was also reported to eliminate, or reduce, the detrimental effects of storage 
conditions on the fine particle dose of DPI formulations (Bulsara and Roche, 2005).  Similar 
observations were reported by Monteith and Thomas (2006), who described the use of 
magnesium stearate as a ternary agent to inhibit or reduce chemical interaction between an 
API and a carrier in a solid pharmaceutical formulation, wherein the API is susceptible to 
chemical interactions with the carrier. It was suggested that the role of magnesium stearate, 
and sugar esters such as cellubiose acetate, as inhibitors of chemical interactions may be 
related to the findings that, under accelerated stability conditions, certain inhalable APIs 
undergo degradation in the presence of lactose. It was proposed that this type of chemical 
reaction may proceed via the Maillard reaction, as suggested by Wirth et. al. (1998) for the 
drug Prosac®, who reported that drug substances, which have secondary or primary amine 
moeities, as have many small molecule respiratory drug substances, can undergo the 
Maillard reaction with lactose under pharmaceutically relevant conditions. However, many 
long acting beta agonist respiratory drug substances in approved products, contain such a 
similar N-substituted aminohydroxyethylbenzene type secondary amine structures to 
vilanterol, for example, formoterol, indacaterol and salmeterol, see Figure 7. Moreover, 
commercialisation of the latter 3 compounds in DPI products has been achieved without the 
incorporation of any ternary excipient suggesting that, as expected, the relationships 
between chemical interactions and delivery systems and shelf-life in DPI products are 
complex.    
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7.9 The use of magnesium stearate in DEP capsule based DPI products 
The role of such DEPs based on lactose monohydrate and magnesium stearate has also been 
demonstrated to be equally applicable to other DPI platforms beyond blister based 
products. Indeed, the public European product information and US prescribing information 
for the two recently approved capsule based products, the mono therapy 
Seebri®Breezhaler®/Seebri™Neohaler® (glycopyrronium bromide), and the combination 
therapy Ultibro®Breezhaler®/Utibron™Neohaler® (glycopyrronium bromide and indacaterol 
maleate), both developed by Novartis, show that both the products also contain the two 
excipients magnesium stearate and lactose monohydrate, see Figure 8 and Table 3.  
 
It is interesting to note that the indacaterol maleate component in the co-formulated 
combination product Ultibro®Breezhaler®/Utibron™Neohaler® is also approved as the mono 
therapies, Onbrez®Breezhaler®/Arcapta™Neohaler™ in Europe and US, respectively, but this 
product only contains lactose monohydrate. This is similar to the excipient strategy diversity 
situation with the previously discussed GSK mono and combination products and again 
suggests that the functional properties of the indacaterol maleate formulations in the mono 
therapies are sufficient without any additional magnesium stearate, further demonstrating 
the continuing flexible development approaches used during DPI product development.   
 
The public US prescribing information and European product information also suggest that 
the two Novartis DEP products contain similar masses of lactose monohydrate to the 
Novartis SEP product, Onbrez®Breezhaler®/Arcapta™Neohaler™, approximately 25 mg. 
Additionally, the public US prescribing information for Seebri™Neohaler® and 
Utibron™Neohaler® also states that the glycopyrronium bromide and glycopyrronium 
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bromide/indacaterol maleate formulations also contain magnesium stearate, at 
concentrations of 0.16% and 0.12%, respectively, see Table 3. This small apparent difference 
in magnesium stearate levels for similar mass formulations suggests that the functional 
benefits of magnesium stearate can vary between formulations. However, it should be 
noted that the levels of magnesium stearate in the Novartis DEP products are almost an 
order of magnitude lower than the magnesium stearate levels in the GSK DEP products, 
suggesting that the functional benefits of a ternary material are drug substance, formulation 
and product specific. Indeed it was suggested by Monteith and Thomas (2006) that the 
optimal amount of magnesium stearate in a DEP formulation would vary depending on, for 
example, the API, and the particle size.  
 
In terms of the functional development of ternary excipients in the Novartis DEP products, 
the public CHMP assessments of Seebri®Breezhaler® and Ultibro®Breezhaler® also describe 
the functionality of the lactose monohydrate in both formulations as a ‘carrier’, see Table 3. 
Whilst there is no information concerning the functionality of the magnesium stearate, the 
public CHMP assessment of Seebri®Breezhaler® describes some interesting insights into the 
functionality of the excipients in this DEP product in that that the micronised active 
substance is described as being ‘stabilised by an added excipient’; another reference to the 
stabilising functionality of excipients in DPI products. Additionally, in contrast to the 2 DEP 
GSK products, where the public CHMP assessments simply describe ‘blending’ 
manufacturing processes, the public CHMP assessment of Seebri®Breezhaler® describes the 
manufacturing process of the finished product which involves the preparation of a 
‘pharmaceutical intermediate which is then blended with excipients and filled into hard 
capsules’. The limited availability of information concerning the manufacturing of the blister 
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and capsule based DEP products does indicate that different process strategies may be 
being used to achieve the desired outcomes, again reflecting the flexible and innovative 
approaches made during development. 
 
Equally of interest is that for the 3 Novartis commercialised products, 
Onbrez®Breezhaler®/Arcapta™Neohaler™, Seebri®Breezhaler®/Seebri™Neohaler® and 
Ultibro®Breezhaler®/Utibron™Neohaler® the public CHMP assessments and US prescribing 
information suggest two different capsule types have been used with hypromellose being 
used in the DEP products Seebri®Breezhaler®/Seebri™Neohaler®, and 
Ultibro®Breezhaler®/Utibron™Neohaler®, and gelatin in the SEP product, 
Onbrez®Breezhaler®/Arcapta™Neohaler™. Since the hypromellose and gelatin capsules 
have different characteristics, such as water content, the use of different capsule materials 
offers another formulation option when considering development strategies for DPIs 
(Richardson, 2011). 
7.10 The use of magnesium stearate in DEP reservoir based DPI products 
The universality of the DEP would not be complete without its use in reservoir based DPI 
products, which has, indeed, been achieved. As previously mentioned, the first modern 
commercial DEP DPI product, Pulvinal®Beclometasone®, was developed by Chiesi as a multi-
dose reservoir based product, followed by the Novartis multi-dose reservoir product 
Foradil®Certihaler®. Chiesi have followed the same ‘reservoir’ based strategy with the 
approval in 2012 of the DEP beclometasone dipropionate/formoterol fumarate co-
formulated combination reservoir DPI product, Foster®NEXThaler®, see Figure 9. This again 
suggests that the development strategies of pharmaceutical companies tend to be based on 
attempting to minimise development risks by manipulating formulations and using well 
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understood, albeit internal and often propriety, processing operations. The public summary 
of product characteristics of Fostair®NEXThaler® (the UK brand of Foster®NEXThaler®), from 
2014, states that the product contains the two excipients, lactose monohydrate and 
magnesium stearate, which is similar to the two excipients used in the previously discussed 
commercial blister and capsule based DEP DPI products.  
8. Conclusions  
For many decades DPI products have been successfully developed using a variety of 
formulation strategies including drug only or powder mixture approaches containing a single 
excipient, typically lactose monohydrate. Single excipient based formulations continue to be 
used in approved commercial DPI products today. However, since 2010 there has been a 
major diversification in the formulation strategies successfully used and implemented in 
approved DPI products. The early fundamental studies and pharmaceutical innovations of 
Hersey, Monteith, Thomas, Staniforth, Chiesi etc., and their co-workers, has finally resulted 
in the successful development, understanding and implementation of novel DEP strategies 
in commercialised DPI products. These innovations have not only allowed the expansion of 
DPI development options for pharmaceutical companies but, importantly, also the 
availability of an increasing range of medicines that are beneficial to patients. 
 
All trademarks referenced within this article are owned by the respective third parties. 
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